SHIFT AI Newsroom · GLOBAL
Trial to Assess Efficacy and Safety of AT673 with Semaglutide in Type 2 Diabetes and Overweight/Obesity
A clinical trial is underway to evaluate the efficacy, safety, and tolerability of AT673 co-administered with semaglutide in adults with type 2 diabetes and overweight or obesity.
A clinical trial has been registered on ClinicalTrials.gov to assess the efficacy, safety, and tolerability of AT673 when co-administered with semaglutide in adult participants with type 2 diabetes (T2D) and overweight or obesity. The trial's details, including its outcomes, are awaited.
What this means in the UK
This trial may potentially lead to new treatment options for adults in the UK with type 2 diabetes and overweight or obesity, but its impact and availability in the UK are unknown at this stage.
Known facts
- A clinical trial is assessing the efficacy, safety, and tolerability of AT673 co-administered with semaglutide in adults with type 2 diabetes and overweight or obesity.